Skip to content
Screener

Penumbra PEN Embolization and Other — Revenue

Other product segments

Thrombectomy
$253.92M+12.1%
Embolization and Access
$120.84M+23.8%

Similar metrics at other companies

Flywire Corporation logo
FLYWPlatform And Other Revenues — Revenue
$31.85M+1.7%
Lennar logo
LENOther revenues — Revenue
$331.4M-6.8%
PROG Holdings logo
PRGOther Revenues — Revenue
$21.62M+165%
Flanigan's Enterprises logo
BDLOther Revenues — Revenue
$88K+27.5%
Enbridge logo
ENBTransportation And Other Services Revenues — Revenue
$5.03B-4.3%
Century Communities logo
CCSLand Sales And Other — Revenue
$4.26M+781%

Other financials

Income statement

See full
Revenue$374.8M+15.6%
Gross profit$253.4M+17.4%
Operating income$38.2M-5.2%
Net income$32.6M-16.9%
EPS (diluted)$0.82-18.0%

Balance sheet

See full
Cash & equivalents$241.3M-35.8%
Total debt$216.2M-2.0%
Total equity$1.5B+21.5%
Total assets$1.9B+19.2%

Cash flow

See full
Operating cash flow$87.0M+77.6%
CapEx$13.7M+1.5%
Free cash flow$73.3M+106%

Valuation

See full
Market cap$12.73B+36.0%
Enterprise value$12.71B+38.7%
P/E74.4×+11.1×
P/S8.8×+1.4×

Profitability

See full
Gross margin67.4%+3.7pp
Operating margin12.9%+9.8pp
Net margin11.8%+8.4pp
FCF margin14.6%+2.5pp

Returns & leverage

See full
Return on equity12.7%+9.2pp
Debt / equity0.1×0.0×
Current ratio6×-0.3×

Where this comes from

Reported directly by Penumbra in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Penumbra’s 10-K, filed February 25, 2026.

Filed
Feb 25, 2026, 1:27 PM EST
Fiscal year
FY2025
Accession
0001321732-26-000007
Line itemYear Ended December 31, 2025Year Ended December 31, 2024Year Ended December 31, 2023
Revenue$1,403,665$1,194,615$1,058,522
Cost of revenue461,228439,620375,879
Gross profit942,437754,995682,643
Operating expenses:
Research and development89,76694,78384,423
Sales, general and administrative663,422573,988506,454
Acquired in-process research and development——18,215
Impairment charge—76,945—

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

FAQ

What is Penumbra's embolization and other — revenue?
Penumbra (PEN) reported embolization and other — revenue of $113.94M in Q4 2025.
How has Penumbra's embolization and other — revenue changed year-over-year?
Penumbra's embolization and other — revenue increased by 20.2% year-over-year, from $94.79M to $113.94M.
What is the long-term trend for Penumbra's embolization and other — revenue?
Over 4 years (2021 to 2025), Penumbra's embolization and other — revenue has grown at a 10.1% compound annual growth rate (CAGR), from $309.82M to $455.75M.
What does embolization and other — revenue mean?
This metric represents the total net sales generated from the embolization product portfolio and associated secondary medical device offerings. It captures revenue streams derived from specialized tools used by physicians to occlude blood vessels or treat vascular malformations. This segment serves as a critical component of the company's broader vascular intervention strategy.

Ask your AI about Penumbra's embolization and other — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude